Psychometric validation of the Worst Itch Numerical Rating Scale (WI-NRS) and other patient-reported outcome measures for assessing severity and impact of pruritus in patients with primary biliary cholangitis
- PMID: 40745549
- PMCID: PMC12315290
- DOI: 10.1186/s13023-025-03798-x
Psychometric validation of the Worst Itch Numerical Rating Scale (WI-NRS) and other patient-reported outcome measures for assessing severity and impact of pruritus in patients with primary biliary cholangitis
Abstract
Background: Cholestatic pruritus is common in primary biliary cholangitis (PBC), often leading to sleep disturbances and substantially impairing health-related quality of life (HRQoL). Fatigue, also frequent in PBC, can be exacerbated by sleep interference due to nighttime pruritus. Quantitative numerical rating scales (NRS) are appropriate for assessing unidimensional patient-reported outcome (PRO) concepts and are easily interpreted. The PBC-40 is a disease-specific, patient-derived 40-item tool that assesses HRQoL in patients with PBC. To assess pruritus severity in clinical trials, rigorous validation of PROs in the target patient population is required. This study aimed to validate the NRS items for worst itch (WI-NRS), pruritus-related sleep interference (Sleep Interference NRS), and fatigue (Fatigue NRS), plus the PBC-40 (modified with a 7-day recall), among patients with PBC and pruritus.
Methodology: Data were analyzed from the Phase 2b GLIMMER trial (NCT02966834) of linerixibat and a separate observational study in patients with PBC and pruritus. Pruritus severity was assessed using the 0-10 WI-NRS. Psychometric properties of the WI-NRS, Sleep Interference NRS, Fatigue NRS, and PBC-40 (7-day recall) were evaluated. Additional PRO data were used to support validation analyses. Multiple psychometric methods were used to validate the NRS items and PBC-40 (7-day recall).
Results: Data for 288 patients (n=147 GLIMMER; n=141 observational study) with PBC experiencing pruritus were included. The internal consistency of PBC-40 (7-day recall) was acceptable to excellent and confirmatory factor analysis confirmed its domain structure. All PBC-40 domains showed acceptable test-retest reliability (intraclass correlation coefficients [ICCs]: 0.72-0.90). The WI-NRS showed acceptable test-retest reliability (ICCs: 0.73-0.81 [GLIMMER]; ICC: 0.78 [observational study]). Test-retest reliability was also acceptable for the Sleep Interference (ICC: 0.85 [GLIMMER]; ICC: 0.77 [observational study]) and Fatigue (ICC: 0.88 [GLIMMER]; ICC: 0.78 [observational study]) NRS items. Convergent, discriminant, and known-groups validity were confirmed for all three NRS items and the PBC-40. Additionally, the NRS and PBC-40 Itch domain demonstrated responsiveness by reflecting change in other PROs over time.
Conclusions: The data support the psychometric reliability, validity, and responsiveness of WI-NRS, pruritus-related Sleep Interference NRS, and Fatigue NRS, and PBC-40 (7-day recall) in patients with PBC experiencing pruritus.
Keywords: 5-D itch scale; Cholestatic pruritus; Fatigue; Itch; Numerical rating scale; PBC-40; Patient-reported outcomes; Primary biliary cholangitis; Psychometric validation; Sleep interference.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Both the GLIMMER and observational study protocol were reviewed and approved by an ethics committee or institutional review board. Consent for publication: As part of the study participation consent, participants provided written consent for their anonymized data to be published. Competing interests: BMC, MMM, and RvM are employed by GSK and hold financial equities in GSK. HG, DMB, MLM, FF, and HK are employees of Evidera, who was funded by GSK to carry out the observational study and psychometric analyses using the GLIMMER data. MJM has received research support from CymaBay, GSK, Intercept, Ipsen, Mallinckrodt and Mirum, and has consulted for CymaBay, GSK, and Mallinckrodt. DEJ has received grant funding or fees from Abbott, Falk, GSK, Intercept, Novartis, and Pfizer. Study conduct and data analysis were performed by Evidera funded by GSK. No funding was provided to Evidera for manuscript development.
Figures

Similar articles
-
Relationship between pruritus and sleep in participants with primary biliary cholangitis in the Phase 2b GLIMMER trial.J Patient Rep Outcomes. 2024 Jun 12;8(1):60. doi: 10.1186/s41687-024-00722-y. J Patient Rep Outcomes. 2024. PMID: 38862718 Free PMC article. Clinical Trial.
-
A New Measure of Quantified Social Health Is Associated With Levels of Discomfort, Capability, and Mental and General Health Among Patients Seeking Musculoskeletal Specialty Care.Clin Orthop Relat Res. 2025 Apr 1;483(4):647-663. doi: 10.1097/CORR.0000000000003394. Epub 2025 Feb 5. Clin Orthop Relat Res. 2025. PMID: 39915110
-
Assessment of PBC Pruritus From the ITCH-E Study: Quality of Life, Productivity, and Treatment Experiences.Liver Int. 2025 Sep;45(9):e70276. doi: 10.1111/liv.70276. Liver Int. 2025. PMID: 40847640 Free PMC article.
-
Exercise interventions on health-related quality of life for people with cancer during active treatment.Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD008465. doi: 10.1002/14651858.CD008465.pub2. Cochrane Database Syst Rev. 2012. PMID: 22895974 Free PMC article.
-
Pharmacological interventions for pruritus in adult palliative care patients.Cochrane Database Syst Rev. 2013 Jun 9;(6):CD008320. doi: 10.1002/14651858.CD008320.pub2. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2016 Nov 15;11:CD008630. doi: 10.1002/14651858.CD008630.pub4. Update in: Cochrane Database Syst Rev. 2016 Nov 16;11:CD008320. doi: 10.1002/14651858.CD008320.pub3. PMID: 23749733 Updated.
References
-
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–72. 10.1016/j.jhep.2017.03.022. - PubMed
-
- Hegade VS, Mells GF, Fisher H, Kendrick S, DiBello J, Gilchrist K, Alexander GJ, Hirschfield GM, Sandford RN, Jones DEJ, the UK-PBC Consortium. Pruritus is common and undertreated in patients with primary biliary cholangitis in the united Kingdom. Clin Gastroenterol Hepatol. 2019;17(7):1379–1387.E3. 10.1016/j.cgh.2018.12.007. - PubMed
-
- Mayo MJ, Carey E, Smith HT, Mospan AR, McLaughlin M, Thompson A, Morris HL, Sandefur R, Kim WR, Bowlus C, the TARGET-PBC Investigators, Levy C. Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis. Dig Dis Sci. 2023;68(3):995–1005. 10.1007/s10620-022-07581-x. - PMC - PubMed
-
- Pate J, Gutierrez JA, Frenette CT, Goel A, Kumar S, Manch RA, Mena EA, Pockros PJ, Satapathy SK, Yimam KK, Gish RG. Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel. BMJ Open Gastroenterol. 2019;6(1):e000256. 10.1136/bmjgast-2018-000256 - PMC - PubMed
-
- Oeda S, Takahashi H, Yoshida H, Ogawa Y, Imajo K, Yoneda M, Koshiyama Y, Ono M, Hyogo H, Kawaguchi T, Fujii H, Nishino K, Sumida Y, Tanaka S, Kawanaka M, Torimura T, Saibara T, Kawaguchi A, Nakajima A, Eguchi Y, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Prevalence of pruritus in patients with chronic liver disease: a multicenter study. Hepatol Res. 2018;48(3):E252–62. 10.1111/hepr.12978 - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous